Pharma Knowledge Management Software Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented, By Deployment, By Organization Size, By Region & Competition, 2021-2031F

The Global Pharma Knowledge Management Software Market is projected to expand significantly, rising from USD 5.62 Billion in 2025 to USD 15.94 Billion by 2031, reflecting a compound annual growth rate of 18.98%. These platforms serve as specialized digital systems designed to capture, organize, and retrieve proprietary information throughout the drug development lifecycle, spanning from initial discovery to final commercialization. Critical for safeguarding intellectual property and maintaining strict regulatory compliance, these systems also enable seamless collaboration among geographically dispersed research teams. Key growth factors include the urgent need to speed up the time-to-market for new treatments, the requirement for audit-ready documentation, and the necessity to prevent knowledge loss caused by employee turnover or organizational restructuring.

However, the market faces a substantial obstacle in the form of data fragmentation and the abundance of unstructured legacy information. Merging isolated data silos into a cohesive repository presents a difficult technical and cultural challenge for many pharmaceutical enterprises. According to the Pistoia Alliance, in 2024, 52% of life science experts pinpointed low-quality and poorly curated datasets as the primary hindrance to adopting advanced R&D technologies. This statistic highlights the significant struggle pharmaceutical companies face in harmonizing their extensive information archives into accessible and actionable intelligence.

Market Driver

The increasing integration of cloud-based and AI-powered knowledge solutions is fundamentally transforming how pharmaceutical companies manage their intellectual property. As organizations move away from isolated legacy systems toward interconnected digital ecosystems, these advanced technologies are facilitating real-time data access and improved decision-making. This transition is essential for managing the vast amounts of unstructured data produced by modern R&D, enabling scientists to quickly locate and synthesize information across global teams. According to the Pistoia Alliance, in September 2025, 77% of life sciences laboratories anticipate using artificial intelligence technologies within the next two years, indicating a clear shift toward automated and intelligent knowledge management infrastructures.

Simultaneously, the pressure to accelerate drug discovery and shorten time-to-market is compelling companies to refine their data pipelines to achieve aggressive commercial goals. Given that patent lifecycles are limited and development costs are high, knowledge management software serves as a crucial backbone for streamlining workflows and preventing duplicative research. This drive for rapid innovation is illustrated by major industry leaders setting high output targets; for instance, Roche announced in 2025 a strategic goal to launch 20 new breakthrough therapies by 2029. To sustain such high-velocity innovation, significant capital is flowing into digital and biotech advancements, as seen in October 2025 when Sanofi increased its corporate venture capital fund to $1.4 billion to specifically invest in artificial intelligence and digital health technologies.

Market Challenge

The prevalence of data fragmentation and unstructured legacy information stands as a major obstacle to the growth of the global pharma knowledge management software market. Pharmaceutical companies often face difficulties in consolidating proprietary data that is dispersed across isolated silos and stored in inconsistent formats throughout the drug development process. This lack of connectivity hinders the establishment of a unified repository, which is essential for the successful implementation of knowledge management platforms. When vital research data remains locked in disparate systems without a standardized framework, organizations encounter significant operational delays and higher costs due to manual data retrieval, effectively negating the efficiency benefits these software solutions are meant to deliver.

These persistent technical barriers restrict the addressable market for vendors, as potential customers are reluctant to invest in platforms that struggle to integrate with their current infrastructure. The failure to effectively harmonize various data sources halts digital transformation efforts. According to the Pistoia Alliance, in 2024, 60% of life science professionals identified the lack of data interoperability and integration capabilities as a leading impediment to adopting data-centric technologies. This statistic underscores a critical market friction, where the resource-heavy task of structuring legacy data compels enterprises to redirect budget and attention away from software acquisition, thereby slowing overall market expansion.

Market Trends

The integration of Generative AI for Automated Content Synthesis is reshaping knowledge management systems, elevating them from passive storage units to active intelligence engines. Pharmaceutical entities are increasingly leveraging these capabilities to automate the generation of complex documents, such as clinical study reports, safety summaries, and regulatory submissions, which reduces manual workload and minimizes human error. This trend directly tackles the bottleneck of regulatory writing by using large language models to extract and synthesize pertinent findings from extensive historical data. According to PharmaTimes in July 2024, the 'GenAI out of the bottle' report noted that 53% of regulatory professionals recognized a specific need to use artificial intelligence for information summarization to streamline these labor-intensive documentation tasks.

Concurrently, the adoption of Semantic Search and Enterprise Knowledge Graphs is becoming a structural necessity to support these advanced AI workflows. To ensure generative models deliver accurate and reliable outputs, companies are moving from unstructured data lakes to semantically linked knowledge graphs that ensure data contextualization and traceability. This evolution is driven by the need to make proprietary data Findable, Accessible, Interoperable, and Reusable (FAIR) throughout the drug development lifecycle. According to the Pistoia Alliance's 'Lab of the Future 2024 Global Survey' in September 2024, 38% of life science respondents identified data that fails to adhere to FAIR principles as a major hurdle to the effective implementation of AI technologies, highlighting the urgency of this architectural shift.

Key Market Players

• SAP SE
• Oracle Corporation
• Dassault Systemes SE
• ArisGlobal LLC
• MasterControl Inc.
• Accenture plc
• IQVIA Holdings Inc.
• Veeva Systems Inc.
• Honeywell International Inc.
• Sparta Systems Inc.

Report Scope

In this report, the Global Pharma Knowledge Management Software Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharma Knowledge Management Software Market, By Deployment

• On-Premises
• Cloud
• Hybrid

Pharma Knowledge Management Software Market, By Organization Size

• Small & Medium Enterprises
• Large Enterprises

Pharma Knowledge Management Software Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharma Knowledge Management Software Market.

Available Customizations:

Global Pharma Knowledge Management Software Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).